AeroLeads people directory · profile
Gregory Adams Email & Phone Number
Senior Vice President, Research
at
Calytrix Bio
1 work email found
@elucidaoncology.com
2 phones found area 888 and 215
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
Senior Vice President, Research
Location
Greater Philadelphia, United States
Who is Gregory Adams? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Gregory Adams is listed as Senior Vice President, Research at Calytrix Bio, based in Greater Philadelphia, United States. AeroLeads shows a work email signal at elucidaoncology.com, phone signal with area code 888, 215, and a matched LinkedIn profile for Gregory Adams.
Gregory Adams previously worked as Consultant at Greg Adams Consulting and Scientific Advisory Board Member at Integral Molecular. Gregory Adams holds Ph.D., Immunology from University Of California, Davis.
Company email context
Email format at Calytrix Bio
This section adds company-level context without repeating Gregory Adams's masked contact details.
{first_initial}{last}@elucidaoncology.com
86% confidence
AeroLeads found 1 current-domain work email signal for Gregory Adams. Compare company email patterns before reaching out.
Profile bio
About Gregory Adams
Immunologist with over 30 years experience in developing antibody-based agents for the treatment and detection of cancer. Chief Scientific Officer at Elucida Oncology. Elucida is a preclinical stage oncology company developing targeted ultra-small nanodrug conjugates based upon the C'Dot platform.Formerly Chief Scientific Officer at Sesen Bio/Eleven Bio and Chief Development Officer at Eleven/Viventia Bio, Director of Biological Research and Therapeutics at Fox Chase Cancer Center (FCCC) and Co-leader of the Developmental Therapeutics Program at FCCCCo-founder and former acting CEO of RAbD Biotech LLC, a start up company that used in silico design methods to design biotherapeutics.Previously headed a lab at FCCC focused on engineering/evaluating antibodies and antibody-drug conjugates for the treatment of cancer and on developing antibody-based biosensors. Merrimack Pharmaceutical's anti-HER2/HER3 bispecific antibody MM-111, which made it to phase 2 trials, was developed by my group in collaboration with Jim Marks (UCSF) and licensed to Merrimack.I serve on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals and rotated off the editorial board of Cancer Research. I was a member of the Integration Panel of the Department of Defense's Breast Cancer Research Program and served as a reviewer for other panels including the NCI and the ACS and am a member of the Antibody Society's Board of Directors. Prior to joining Viventia Bio I was an adviser to biotech companies such as Endo Pharmaceuticals, Mersana, Symphogen, Avipep, AvidBiologics. I was as an expert witness for Centocor/J&J in a patent infringement lawsuit against Abbott (Remicade vs. Humira).
Listed skills include Cancer, Immunology, Biotechnology, Oncology, and 37 others.
Current workplace
Gregory Adams's current company
Company context helps verify the profile and gives searchers a useful next step.
27 roles · 26 years
Gregory Adams work experience
A career timeline built from the work history available for this profile.
Consultant
Scientific Advisory Board Member
Chief Scientific Officer
Elucida Oncology was a clinical stage company developing targeted ultra-small C'-dot (nanoparticle) Drug Conjugates (CDCs) for the treatment of cancer. CDCs built upon the successes of antibody drug conjugate (ADC) technology and addressed the limitations of ADCs by delivering payloads deep into tumors and accessing tumors in difficult to target locations like the brain.
Aug 2019 - Jun 2024
Chief Scientific Officer
Sesen Bio
Note: Eleven Bio changed its name to Sesen Bio in May of 2018. As CSO I focused on guiding the development of the product line of sesen bio (Eleven Bio) which is primarily focused on antibody-based fusion proteins containing potent toxins capable of killing dividing and non-dividing cancer cells. My role included identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was also part of the team working on securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts and investment groups as the need arises.
Jan 2017 - Mar 2019
Chief Development Officer
Sesen Bio
Following the acquisition of Viventia by Eleven Biotherapeutics I joined the management team of Eleven as the Chief Development Officer. My position was focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I was part of the team working on Securing additional financial investment into Eleven Biotherapeutics, presenting the company to bankers, analysts and investment groups.
Sep 2016 - Jan 2017
Chief Development Officer
I joined Viventia Bio as their Chief Development Officer in May of 2015. My evolving position is focused on guiding the development of the product line including identification of new technologies for in licensing, establishing strategic collaborations and moving leads into clinical trials. I am also part of the team working on Viventia's IPO and presenting the company to bankers, analysts and in testing the waters meetings with investment groups.
May 2015 - Sep 2016
Member: Scientific Advisory Board
2001 - May 2015
Adjunct Associate Professor
Adjunct Assoc. Professor in the Molecular Therapeutics Program at Fox Chase Cancer Center.
May 2015 - May 2016
Director Of Biological Research And Therapeutics
This position evolved from my prior role as a founder and Co-leader of the Developmental Therapeutics Program at the Fox Chase Cancer Center. One of my key goals in this position is to foster collaborations between Fox Chase Physicians and Scientists and their counterparts in pharma, biotech and other academic institutions that lead to the development of new biologic agents for the detection and treatment of cancer.
Dec 2013 - May 2015
Associate Professor
Tenured member of the faculty of the Developmental Therapeutics Program
Jun 2008 - May 2015
Tenured Faculty Member
Lead a research group focused on developing antibody-based agents for the treatment of cancer.
2008 - May 2015
Co-Leader - Developmental Therapeutics Program
Co-leader of one of the five academic research programs (Departments) at Fox Chase Cancer Center in Philadelphia. The Developmental Therapeutics Program is a collaborative effort between basic science researchers and cancer physicians with expertise in clinical trials. We seek to understand the fundamental molecular events that drive cancer and exploit this knowledge in the development of novel therapeutics.
Jan 2009 - Dec 2013
Associate Member
2001 - 2008
~7 yrs
Assistant Member
Jun 1994 - 2001
Adjunct Associate Professor
Mar 2008 - 2016
Scientific Advisory Board Member
Sevion Therapeutics
May 2014 - May 2015
Ceo And Co-Founder
Co-founder of RAbD Biotech LLC, a start up focused on rationally developing biotherapeutics including hormones and antibodies using knowledge of the 3D structure and sequence of the desired therapeutic target. We are using knowledge of protein structure and in silico design methods to design and produce agents that specifically bind to functional sites on receptors or other functional targets. Our primary focus is highly conserved sequences that are difficult to target using currently available methods.Our lead agent is RAD-003, a first-in-class biologic agent for the treatment of ovarian cancer.
Jan 2014 - May 2015
Scientific Advisory Board Member
Jan 2013 - May 2015
Oct 2011 - May 2015
Chief Scientific Advisor
Avid Biologics (Renamed Formation Biologics)
Jan 2011 - May 2015
Member: Scientific Advisory Board
Avipep
2008 - May 2015
Oncology Advisory Board Member
May 2010 - Jun 2014
Consultant
High-level consultation for Teva Pharmaceuticals on an in licensing / acquisition opportunity.
May 2014 - May 2014
Scientific Advisory Board Member
Ym Biosciences
Member of YM's SAB until it was acquired by Gilead Sciences, Inc.
Jun 2010 - Mar 2013
Member: Scientific Advisory Board
Solixia
2008 - 2011
~3 yrs
Expert Witness
Served as an expert witness on behalf of Centocor in the Remicade vs Humira patent infringement lawsuit filed against Abbott Pharmaceuticals. Prepared and reviewed expert opinions on infringement, enablement, written description and testified in the jury trial in Marshall Texas.
Oct 2008 - Jul 2009
2 education records
Gregory Adams education
Ph.D., Immunology
University Of California, Davis
Ba, Biology
University Of California, Santa Cruz
FAQ
Frequently asked questions about Gregory Adams
Quick answers generated from the profile data available on this page.
What company does Gregory Adams work for?
Gregory Adams works for Calytrix Bio.
What is Gregory Adams's role at Calytrix Bio?
Gregory Adams is listed as Senior Vice President, Research at Calytrix Bio.
What is Gregory Adams's email address?
AeroLeads has found 1 work email signal at @elucidaoncology.com for Gregory Adams at Calytrix Bio.
What is Gregory Adams's phone number?
AeroLeads has found 2 phone signal(s) with area code 888, 215 for Gregory Adams at Calytrix Bio.
Where is Gregory Adams based?
Gregory Adams is based in Greater Philadelphia, United States while working with Calytrix Bio.
What companies has Gregory Adams worked for?
Gregory Adams has worked for Calytrix Bio, Greg Adams Consulting, Integral Molecular, Elucida Oncology, Inc., and Sesen Bio.
How can I contact Gregory Adams?
You can use AeroLeads to view verified contact signals for Gregory Adams at Calytrix Bio, including work email, phone, and LinkedIn data when available.
What schools did Gregory Adams attend?
Gregory Adams holds Ph.D., Immunology from University Of California, Davis.
What skills is Gregory Adams known for?
Gregory Adams is listed with skills including Cancer, Immunology, Biotechnology, Oncology, Cancer Research, Life Sciences, Molecular Biology, and Antibodies.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial